# Nivolumab in Combination With TACE/TAE for Patients With Intermediate Stage HCC

> **NCT04268888** · PHASE2,PHASE3 · SUSPENDED · sponsor: **The Clatterbridge Cancer Centre NHS Foundation Trust** · enrollment: 522 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Nivolumab and TACE/TAE
- **PROCEDURE:** TACE/TAE

## Key facts

- **NCT ID:** NCT04268888
- **Lead sponsor:** The Clatterbridge Cancer Centre NHS Foundation Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2019-05-08
- **Primary completion:** 2025-08-01
- **Final completion:** 2026-06-30
- **Target enrollment:** 522 (ESTIMATED)
- **Why stopped:** Analysis meant the study should close to recruitment
- **Last updated:** 2025-02-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04268888

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04268888, "Nivolumab in Combination With TACE/TAE for Patients With Intermediate Stage HCC". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT04268888. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*